• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by La Jolla Pharmaceutical Company (Amendment)

    2/14/22 9:26:36 AM ET
    $LJPC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LJPC alert in real time by email
    SC 13G/A 1 p22-0732sc13ga.htm LA JOLLA PHARMACEUTICAL COMPANY

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  3)*
     

    La Jolla Pharmaceutical Company

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    503459604

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 50345960413G/APage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,590,932 Shares (including 263,029 Shares issuable upon conversion of Preferred Shares) (See Item 4)

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,590,932 Shares (including 263,029 Shares issuable upon conversion of Preferred Shares) (See Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,590,932 Shares (including 263,029 Shares issuable upon conversion of Preferred Shares) (See Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.3% (See Item 4)

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 50345960413G/APage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,590,932 Shares (including 263,029 Shares issuable upon conversion of Preferred Shares) (See Item 4)

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,590,932 Shares (including 263,029 Shares issuable upon conversion of Preferred Shares) (See Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,590,932 Shares (including 263,029 Shares issuable upon conversion of Preferred Shares) (See Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.3% (See Item 4)

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 50345960413G/APage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is La Jolla Pharmaceutical Company (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 201 Jones Road, Suite 400, Waltham, MA 02451.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:

     

      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Mr. Roderick Wong ("Mr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:

     

      RTW Investments is a Delaware limited partnership.  Mr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the "Shares").

     

     

    CUSIP No. 50345960413G/APage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      503459604

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                         

     

    Item 4. OWNERSHIP:

     

        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
         
        The percentages set forth herein are calculated based upon 27,524,028 Shares outstanding as of October 22, 2021 as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on November 4, 2021, and assumes the conversion of the Series C-1 Convertible Preferred Stock, par value $0.0001 per share, of the Company, (the "Preferred Shares") reported herein.

     

     

    CUSIP No. 50345960413G/APage 6 of 7 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.  RTW Master Fund Ltd., a RTW Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Shares.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 50345960413G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    DATED:  February 14, 2022
     
    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong  
    RODERICK WONG  
         

     

     

     

    Get the next $LJPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LJPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LJPC
    Leadership Updates

    Live Leadership Updates

    See more
    • Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company

      La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Tony Hodges, M.D., FACP, FCCP, as Chief Medical Officer. "We are thrilled to have Tony join our team here at La Jolla," said Larry Edwards, President and Chief Executive Officer of La Jolla. "Tony's clinical experience, operational leadership and in-depth knowledge of critical care medicine are key to helping La Jolla grow net sales of GIAPREZA and XERAVA and become a leader in the critical care space." "I look forward to working with the La Jolla team to continue to

      9/10/21 8:00:00 AM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LJPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Innoviva Completes Acquisition of La Jolla Pharmaceutical

      Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) ("La Jolla") at a price of $6.23 per share (the "Offer Price"), net to the seller in cash, without interest and less required withholding taxes, expired one minute after 11:59 p.m. New York City time on Friday, August 19, 2022. Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercializ

      8/22/22 8:55:00 AM ET
      $INVA
      $LJPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

      Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022 Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022 Sold 15% economic stake in Theravance Respiratory Company ("TRC") to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of existing equity investments TRC previou

      7/27/22 4:05:00 PM ET
      $INVA
      $LJPC
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Innoviva to Acquire La Jolla Pharmaceutical Company

      Acquisition to strengthen Innoviva's infectious disease and hospital portfolio with addition of GIAPREZA® and XERAVA® Innoviva, Inc. (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume-

      7/11/22 7:30:00 AM ET
      $INVA
      $LJPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $LJPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital resumed coverage on La Jolla Pharmaceutical with a new price target

      Chardan Capital resumed coverage of La Jolla Pharmaceutical with a rating of Buy and set a new price target of $15.00

      3/10/21 7:26:04 AM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LJPC
    SEC Filings

    See more
    • SEC Form 15-12G filed by La Jolla Pharmaceutical Company

      15-12G - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)

      9/1/22 8:38:38 AM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by La Jolla Pharmaceutical Company

      S-8 POS - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)

      8/23/22 5:00:55 PM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by La Jolla Pharmaceutical Company

      S-8 POS - LA JOLLA PHARMACEUTICAL CO (0000920465) (Filer)

      8/23/22 5:00:51 PM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LJPC
    Financials

    Live finance-specific insights

    See more
    • Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

      Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021 Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022 Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022 Sold 15% economic stake in Theravance Respiratory Company ("TRC") to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of existing equity investments TRC previou

      7/27/22 4:05:00 PM ET
      $INVA
      $LJPC
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Innoviva to Acquire La Jolla Pharmaceutical Company

      Acquisition to strengthen Innoviva's infectious disease and hospital portfolio with addition of GIAPREZA® and XERAVA® Innoviva, Inc. (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume-

      7/11/22 7:30:00 AM ET
      $INVA
      $LJPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress

      La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress. Corporate Progress Net Product Sales: For the three months ended March 31, 2022, La Jolla's net product sales were $10.4 million, up 21% from the same period in 2021. GIAPREZA U.S. Net Product Sales: For the three months ended March 31, 2022, GIAPREZA U.S. net product sales were $7.7 million, up 13% from the same period in 2021. XERAVA U.S. Net Product Sales: For the three months ended

      5/16/22 4:15:00 PM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LJPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by La Jolla Pharmaceutical Company (Amendment)

      SC 13D/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)

      8/29/22 12:30:46 PM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by La Jolla Pharmaceutical Company

      SC 13D - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)

      8/29/22 12:07:50 PM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by La Jolla Pharmaceutical Company (Amendment)

      SC 13D/A - LA JOLLA PHARMACEUTICAL CO (0000920465) (Subject)

      8/24/22 4:00:26 PM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LJPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Rosen Robert

      4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)

      8/24/22 8:27:43 PM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Ramsay David A returned $623,000 worth of shares to the company (100,000 units at $6.23), closing all direct ownership in the company

      4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)

      8/24/22 8:22:23 PM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Tang Kevin C

      4 - LA JOLLA PHARMACEUTICAL CO (0000920465) (Issuer)

      8/24/22 8:21:25 PM ET
      $LJPC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care